パンクレアスタチンは,インスリン分泌を抑制する新しい臓ペプチドです

K Tatemoto, S Efendić, V Mutt

Nature

|December 4, 1986

まとめ

研究者らは,胰腺の新種のペプチドであるパンクレアスタチンを発見し,インスリン放出を抑制しました. この発見は,糖尿病の理解と治療に影響を与える可能性があります.

科学分野:

バイオケミストリーバイオケミストリー
エンドクリノロジーエンドクリノロジー
分子生物学は分子生物学である.

背景:

C末端アミド構造は,哺乳類における多くの神経活性およびホルモン活性ペプチドの特徴的な特徴である.
既知の神経ペプチドとペプチドホルモンの約50%が,このユニークな化学的特性を有しています.
以前の研究では,脳と腸の抽出物で,C末端のアミド構造を持つ新しいペプチドを特定しました.

研究の目的:

豚の臓抽出物で見つかったC端のグリシンアミドを持つ新しいペプチドを分離し,特徴づけること.
この新発見のペプチドの主要な構造と生物学的活動を決定するために.
インスリン分泌と糖尿病におけるこのペプチドの潜在的な役割を調査する.

主な方法:

化学検出方法を使用して,C端のアミド構造を持つ,以前未知のペプチドを探した.
豚の臓からペプチドの抽出と分離.
ペプチドの主要な構造の決定と,浸透した臓モデルから,グルコース誘発インスリン放出に対するその生物学的活性評価.

主要な成果:

豚の臓からC端のグリシンアミドを含む49残基ペプチドが新しく分離されました.
このペプチドは,グルコース誘発のインスリン放出を強力に抑制しているため,パンクレアスタチンと名付けられた.
パンクレアスタチンはインビトロでインスリン分泌を調節する重要な生物学的活性を示した.

結論:

パンクレアスタチンは,新たに特定されたペプチドホルモンで,インスリン分泌の調節に重要な役割を果たしています.
このペプチドは,糖尿病の病原性に関与している可能性がある.
パンクレアスタチンに関するさらなる研究は,糖尿病治療の新たな治療戦略を提供することができる.

さらに関連する動画

09:35

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform

Published on: July 16, 2016

09:36

Isolated Pancreatic Islet Treatment and Apoptosis Measurement

Published on: May 2, 2025

関連する概念動画

01:58

Cell Specific Gene Expression

Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...

01:05

Insulin Secretory Vesicles

Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...

01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...

01:25

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...

01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...

関連する実験動画